December 27, 2021
Japan’s Ministry of Health, Labor and Welfare (MHLW) approved additional indications for a batch of medicines on December 24 including a combination therapy of Eisai’s multikinase inhibitor Lenvima (lenvatinib) and MSD’s PD-1 inhibitor Keytruda (pembrolizumab). The Lenvima-Keytruda combo obtained its...read more